BRAVENKnow what's real. Now.
Monday, July 27, 2026
world1 outlet covering thisCalibrating

Forte Biosciences stock surges 39% on argenx acquisition deal

First publishedJul 27, 11:23 UTC
Last updatedJul 27, 13:11 UTC · 7m ago
11 outletInvesting.com · Stock Market
Investing.com · Stock Market6Forte Biosciences stock surges 39% on argenx acquisition dealOpen ↗
1 outlets over time — hover a bar for its window & outletslast updated
Forte Biosciences stock surges 39% on argenx acquisition deal
● Story signals

How strong is this topic?

6.0/10Significanceimpact & urgency
6.0/10Source trustoutlet authority
1Outletsindependent sources

Significance weighs impact, urgency & coverage breadth · Source trust is the outlets' average authority · more outlets means a more confirmed story.

Answer

Investing.com -- Forte Biosciences (NASDAQ:FBRX) shares jumped 39% Monday after argenx (NASDAQ:ARGX) announced it will acquire the company for $77 per share in cash, representing a total equity value of approximately $2.2 billion. The acquisition price represents a premium of approximately 86% to Forte Biosciences’ volume-weighted average price since the company reported positive Phase 1b data in vitiligo on July 9, 2026.

Reported by 1 outlet — Investing.com · Stock Market. See all sources ↓

Investing.com -- Forte Biosciences (NASDAQ:FBRX) shares jumped 39% Monday after argenx (NASDAQ:ARGX) announced it will acquire the company for $77 per share in cash, representing a total equity value of approximately $2.2 billion. The acquisition price represents a premium of approximately 86% to Forte Biosciences’ volume-weighted average price since the company reported positive Phase 1b data in vitiligo on July 9, 2026. Under the terms of the merger agreement, argenx will commence a cash tender offer to acquire all outstanding shares of Forte Biosciences’ common stock. The transaction will be funded entirely from cash on hand and is not subject to a financing condition.

Read the full report at Investing.com · Stock Market ↗

Why it matters

A world story we're tracking; its significance and source trust firm up as more outlets confirm it.

In brief
What's the story?
Investing.com -- Forte Biosciences (NASDAQ:FBRX) shares jumped 39% Monday after argenx (NASDAQ:ARGX) announced it will acquire the company for $77 per share in cash, representing a total equity value of approximately $2.2 billion. The acquisition price represents a premium of approximately 86% to Forte Biosciences’ volume-weighted average price since the company reported positive Phase 1b data in vitiligo on July 9, 2026.
How widely is it covered?
1 outlet, average source rating 6.0/10.
When was it last updated?
7m ago.
Different angles across outlets
Coverage map

How outlets are framing the same story

Here's how each outlet is covering the story — compare their headlines and timing at a glance.

  • Coverage card1 outlet
    1Coverage
    Scouting report

    Forte Biosciences stock surges 39% on argenx acquisition deal

    Sources1
    TypeCoverage
    Investing.com · Stock Market
Related in the knowledge graph
organizationARGXorganizationFBRXorganizationForte BiosciencesorganizationInvesting.comorganizationNasdaqorganizationPhaseorganizationT-cellorganizationUnder
Sources (1)
Avg source rating 6.0/10
Processing cluster
A1A2A3B1B2B3
Share this article
X / TwitterLinkedInWhatsApp
Summarize with AI (opens AI chat with article URL · Gemini: prompt copied to clipboard)
GPTPerplexityGeminiClaude